title: Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature.
abstract: OBJECTIVE
  Gastrointestinal lesions of Behçet's disease (BD) are often refractory to medical therapy and sometimes result in serious comorbidities such as gastrointestinal perforation and massive bleeding. There are several reports of patients with BD comorbid with myelodysplastic syndrome (MDS) involving trisomy 8 that frequently have intestinal lesions refractory to conventional medical therapy. Little is known about the efficacy of infliximab (IFX) for these intestinal lesions.
  
  
  METHODS
  We present 2 cases of intestinal BD with MDS involving trisomy 8 who did not respond to IFX, and review previous reports of BD with MDS involving trisomy 8 concerning their responsiveness to conventional medical therapy.
  
  
  RESULTS
  Among 31 previously reported cases that received medical treatment for BD, 19 (61.3%) showed temporary improvement of the BD symptoms, 9 (29.0%) deteriorated, and 3 (9.7%) showed no change. All of the 9 cases that showed deterioration had intestinal lesions. Our 2 cases failed to respond to IFX, resulting in a poor prognosis.
  
  
  CONCLUSIONS
  IFX might not be effective for improving intestinal BD comorbid with MDS involving trisomy 8. Trisomy 8 is associated with the BD prognosis and refractoriness to conventional medical therapy.
authors.affiliation: Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Toyonaga
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakase
authors.forename: Minoru
authors.initials: M
authors.lastname: Matsuura
authors.forename: Naoki
authors.initials: N
authors.lastname: Minami
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamada
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Honzawa
authors.forename: Norimasa
authors.initials: N
authors.lastname: Hukata
authors.forename: Takuya
authors.initials: T
authors.lastname: Yoshino
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Chiba
authors.forename: Kazuichi
authors.initials: K
authors.lastname: Okazaki
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D002898:Chromosomes, Human, Pair 8; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D007410:Intestinal Diseases / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D017211:Treatment Failure; D014314:Trisomy
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab